Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

KB Home

Unum

Telefonica Brasil

We have screened bargain stocks UNM, SNY, KBH, PVH and VIV based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.

Pick These 5 Bargain Stocks With Amazingly Low EV/EBITDA Ratios

Sanofi (SNY) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love Sanofi (SNY)

Eli Lilly

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Sanofi (SNY) or Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?

SNY vs. LLY: Which Stock Is the Better Value Option?

Medallion Financial

Plains All American Pipeline

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like SNY, MFIN, PAA and KBH hold promise.

4 Low Price-to-Sales Stocks to Get the Best of the Market

AstraZeneca

Smith & Nephew

You don't see financial TV channels dedicated to minute-by-minute coverage of dividend yield or increases, but for investors in companies like Sanofi (NASDAQ: SNY), AstraZeneca plc (NASDAQ: AZN), and Smith & Nephew plc (NYSE: SNN), there should be at least a little excitement about intrinsically boosting your stock's return every quarter.

3 Healthcare Dividend Payers With Big Price Growth

Diageo

Novartis

SAP SE

TotalEnergies SE

The consumer price index data showed this week that the rampant inflation that was in place a year ago is slowing, after peaking at 9.1% year-over-year in June of 2022.

5 European Dividend Aristocrats Offer Huge Growth and Income Potential With Diversification From the US

Amgen

Gilead Sciences

Merck

Pfizer

Walgreens

First-quarter earnings kick off in a big way on Friday with the major banks posting their results.

Why 7 of the Highest-Yielding ‘Strong Buy' Health Care Stocks Are the Absolute Best 2023 Buys

Nirsevimab : Sanofi, AstraZeneca and Sobi simplify contractual a greement s Modification of existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of nirsevimab and enhanced agility in the U.S. Existing collaboration agreement with AstraZeneca remains in place for nirsevimab activities ex-U.S. Paris, April 11 , 2023. Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.).

Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

Regeneron Pharmaceuticals

Dupixent's recent clinical data suggest it is a viable treatment option for adult patients with chronic obstructive pulmonary disease (COPD). The medicine could top $3 billion in annual revenue for Sanofi and Regeneron to split.

Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?

Availability of the Q 1 202 3 Memorandum for modelling purposes

Press Release: Availability of the Q1 2023 Memorandum for modelling purposes

Provention Bio Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Provention will receive only $25.00 in cash for each share of Provention that they own.

PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies' jointly developed medication Dupixent.

Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.

Regeneron, Sanofi Look for Billions From COPD Drug

Dupixent was proven to be effective at treating a condition that causes chronic hives. The indication could generate $600 million in annual revenue for Sanofi and Regeneron to share.

Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?

Sanofi is reducing the price of its most important insulin product. A pending acquisition could help pick up the slack in diabetes care.

Is Sanofi Stock a Buy Now?

Amazon

Activision Blizzard

Comcast

Disney

Lululemon Athletica

Marriott

Netflix

NIKE

Vanguard Consumer Staples ETF

Warner Bros Discovery Inc

While you might already know that you can invest in consumer staples like food and tobacco products, you might not know that you can also invest in what people buy when they have more to spend. Consumer discretionary stocks come from companies that produce goods and services that consumers can choose to purchase but are not considered essential to their day-to-day lives.

11 Best Consumer Discretionary Stocks of 2023

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Simplify Health Care ETF

Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.

ETFs in Focus on Sanofi and Regeneron's COPD Drug Data

Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?

Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars appeared first on Investor's Business Daily.

Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.

Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study

Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."

Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD

French pharma multinational Sanofi's Dupixent drug has achieved impressive results in a late-stage trial to treat chronic obstructive pulmonary disease (COPD), aka ‘smoker's lung'. Developed jointly with US biotech group Regeneron, Dupixent caused a 30% reduction in moderate or severe acute exacerbations of COPD among a trial group of 939 current or former smokers.

Sanofi's blockbuster Dupixent drug clears major trial

Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' appeared first on Investor's Business Daily.

News for Sanofi Stock (SNY)